Back to News
Market Impact: 0.3
Pyxis Prices $110 Mln Offering, With Potential Proceeds Of $282 Mln To Advance Lead Cancer Drug
Source: Nasdaq
Healthcare & BiotechCapital Returns (Dividends / Buybacks)
Pyxis Oncology priced a previously announced public offering expected to raise approximately $110 million in gross proceeds. The financing strengthens the clinical-stage biopharmaceutical company's capital base to support ongoing development, though it likely entails shareholder dilution.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
PYXS0.45
More News
- We're raising our Micron price target after an incredible quarter and robust guidance
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- The hottest trade of the year so far isn't AI. It's tanker stocks
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide